{"title": "Wirksamkeit und Sicherheit der COVID-19-Impfung f\u00fcr Patienten mit Lebererkrankungen (CHESS2101)", "author": "Xiaolong Qi", "url": "https://ichgcp.net/de/clinical-trials-registry/NCT04883177", "hostname": "ichgcp.net", "description": "Die COVID-19-Pandemie mit SARS-CoV-2-Infektion ist zu einer globalen Herausforderung geworden. Obwohl die meisten F\u00e4lle von COVID-19 mild verlaufen, kann die Kr.... Register f\u00fcr klinische Studien. ICH GCP.", "sitename": "ichgcp.net", "date": "2021-04-29", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Wirksamkeit und Sicherheit der COVID-19-Impfung f\u00fcr Patienten mit Lebererkrankungen (CHESS2101)\n23. April 2023 aktualisiert von: Xiaolong Qi,\n[Hepatopancreatobiliary Surgery Institute of Gansu Province](https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Hepatopancreatobiliary%20Surgery%20Institute%20of%20Gansu%20Province)\nWirksamkeit und Sicherheit der COVID-19-Impfung f\u00fcr Patienten mit Lebererkrankungen (CHESS2101): eine multizentrische Kohortenstudie\nDie COVID-19-Pandemie mit SARS-CoV-2-Infektion ist zu einer globalen Herausforderung geworden. Obwohl die meisten F\u00e4lle von COVID-19 mild verlaufen, kann die Krankheit auch t\u00f6dlich sein. Patienten mit Lebererkrankungen sind angesichts ihres immungeschw\u00e4chten Status anf\u00e4lliger f\u00fcr Sch\u00e4den durch eine SARS-CoV-2-Infektion. Daher ist die fr\u00fchzeitige Impfung mit SARS-CoV-2-Impfstoff bei Patienten mit Lebererkrankungen eine wichtige Schutzma\u00dfnahme. Informationen zur Wirksamkeit und Sicherheit des COVID-19-Impfstoffs gegen Lebererkrankungen m\u00fcssen jedoch noch ermittelt werden. Diese multizentrische Studie (CHESS2101) zielt darauf ab, die Wirksamkeit und Sicherheit der COVID-19-Impfung f\u00fcr Patienten mit Lebererkrankungen zu untersuchen.\nStudien\u00fcbersicht\nStatus\nAbgeschlossen\nBedingungen\nDetaillierte Beschreibung\nPatienten mit Lebererkrankungen, insbesondere Leberzirrhose, hepatobili\u00e4re Malignome, Kandidaten f\u00fcr eine Lebertransplantation und Personen, die nach einer Lebertransplantation immunsupprimiert sind, haben ein erh\u00f6htes Risiko einer COVID-19-Infektion und eine erh\u00f6hte Sterblichkeit. Daher ist die fr\u00fchzeitige Impfung mit SARS-CoV-2-Impfstoff bei Patienten mit Lebererkrankungen eine wichtige Schutzma\u00dfnahme. Eine kleine Anzahl von SARS-CoV-2-Impfstoffen wurde in klinischen Studien an gesunden Personen getestet und hat Hinweise auf kurzfristige Sicherheit, Immunogenit\u00e4t und Wirksamkeit. Informationen zur Wirksamkeit und Sicherheit des COVID-19-Impfstoffs f\u00fcr Patienten mit Lebererkrankungen m\u00fcssen jedoch noch ermittelt werden. Diese multizentrische Studie (CHESS2101) zielt darauf ab, die Wirksamkeit und Sicherheit der COVID-19-Impfung f\u00fcr Patienten mit Lebererkrankungen zu untersuchen.\nStudientyp\nBeobachtungs\nEinschreibung (Tats\u00e4chlich)\n1000\nKontakte und Standorte\nDieser Abschnitt enth\u00e4lt die Kontaktdaten derjenigen, die die Studie durchf\u00fchren, und Informationen dar\u00fcber, wo diese Studie durchgef\u00fchrt wird.\nStudienkontakt\n- Name: Jitao Wang, MD\n- Telefonnummer: +8618632957579\n- E-Mail:\n[wangjt302@163.com](mailto:wangjt302@163.com?subject=NCT04883177, CHESS2101, Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101))\nStudienorte\n-\nChina\n-\nAnhui\n-\nHefei, Anhui, China\n- The First Affiliated Hospital of Anhui Medical University\n-\n-\nBeijing\n-\nBeijing, Beijing, China\n- Beijing You'an Hospital\n-\n-\nChongqing\n-\nChongqing, Chongqing, China\n- The First Affiliated Hospital of Chongqing Medical University\n-\nChongqing, Chongqing, China\n- Chongqing Fuling Central Hospital\n-\n-\nFujian\n-\nXiamen, Fujian, China\n- The First Affiliated Hospital of Xiamen University\n-\n-\nGansu\n-\nJinchang, Gansu, China\n- Jinchang Central Hospital\n-\nLanzhou, Gansu, China, 730000\n- The First Hospital of Lanzhou University\n-\nQingyang, Gansu, China\n- Qingyang People's Hospital\n-\n-\nGuangdong\n-\nGuangzhou, Guangdong, China\n- The Third Affiliated Hospital of Sun Yat-sen University\n-\n-\nHebei\n-\nXingtai, Hebei, China\n- Xingtai People's Hospital\n-\n-\nHeibei\n-\nBaoding, Heibei, China\n- Baoding People's Hospital\n-\n-\nHenan\n-\nZhengzhou, Henan, China\n- Henan Provincial People's Hospital\n-\n-\nHubei\n-\nWuhan, Hubei, China\n- Wuhan Jinyintan Hospital\n-\n-\nJiangsu\n-\nTaicang, Jiangsu, China\n- The First People's Hospital of Taicang\n-\nWuxi, Jiangsu, China\n- Wuxi Fifth People's Hospital\n-\nZhenjiang, Jiangsu, China\n- The Affiliated Third Hospital of Jiangsu University\n-\n-\nLiaoning\n-\nJinzhou, Liaoning, China\n- Jinzhou Central Hospital\n-\nShenyang, Liaoning, China\n- Sixth People's Hospital of Shenyang\n-\n-\nNingxia Hui Autonomous Region\n-\nYinchuan, Ningxia Hui Autonomous Region, China\n- People's Hospital of Ningxia Hui Autonomous Region\n-\n-\nShandong\n-\nJinan, Shandong, China\n- Shandong Provincial Hospital\n-\nQingdao, Shandong, China\n- Qingdao Sixth People's Hospital\n-\nYantai, Shandong, China\n- Qishan Hospital of Yantai City\n-\n-\nShanghai\n-\nShanghai, Shanghai, China\n- Huashan Hospital Affiliated to Fudan University\n-\n-\nShanxi\n-\nJincheng, Shanxi, China\n- Jincheng People's Hospital\n-\nLinfen, Shanxi, China\n- The Third People's Hospital of Linfen City\n-\nTaiyuan, Shanxi, China\n- Shanxi Bethune Hospital\n-\nTaiyuan, Shanxi, China\n- Taiyuan Third People's Hospital\n-\n-\nSichuan\n-\nChengdu, Sichuan, China\n- Hospital of the Chengdu Office of the People's Government of Tibet Autonomous Region\n-\nYibin, Sichuan, China\n- Yibin First People's Hospital\n-\n-\nTianjin\n-\nTianjin, Tianjin, China\n- Tianjin Second People's Hospital\n-\nTianjin, Tianjin, China\n- Tianjin Third Central Hospital\n-\n-\nTibet\n-\nLasa, Tibet, China\n- The Third People's Hospital of Tibet Autonomous Region\n-\n-\nYunnan\n-\nKunming, Yunnan, China\n- The First People's Hospital of Yunnan Province\n-\nKunming, Yunnan, China\n- Affiliated Hospital of Yunnan University\n-\n-\nZhejiang\n-\nLishui, Zhejiang, China\n- The Central Hospital of Lishui City\n-\nNingbo, Zhejiang, China\n- Beilun Hospital of Traditional Chinese Medicine\n-\nYiwu, Zhejiang, China\n- The Fourth Affiliated Hospital of Zhejiang University\n-\n-\nTeilnahmekriterien\nForscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele f\u00fcr diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder fr\u00fchere Behandlungen.\nZulassungskriterien\nStudienberechtigtes Alter\n18 Jahre und \u00e4lter (Erwachsene, \u00c4lterer Erwachsener)\nAkzeptiert gesunde Freiwillige\nNein\nProbenahmeverfahren\nNicht-Wahrscheinlichkeitsprobe\nStudienpopulation\nPopulationen mit Lebererkrankungen, die die COVID-19-Impfung \u00fcber den gesamten Verlauf abgeschlossen haben\nBeschreibung\nEinschlusskriterien:\n- Klinisch oder pathologisch diagnostiziert mit vorbestehender Lebererkrankung, einschlie\u00dflich: chronische Lebererkrankung, Zirrhose, Leberkrebs, Patienten mit Lebertransplantation usw.;\n- Erhalt der gesamten COVID-19-Impfung f\u00fcr 14 Tage oder l\u00e4nger;\n- Nehmen Sie freiwillig an dieser Studie teil.\nAusschlusskriterien:\n- j\u00fcnger als 18 Jahre;\n- Frauen w\u00e4hrend der Schwangerschaft oder Stillzeit;\n- Recherche zu anderen Situationen, die f\u00fcr die Auswahl als ungeeignet erachtet werden.\nStudienplan\nDieser Abschnitt enth\u00e4lt Einzelheiten zum Studienplan, einschlie\u00dflich des Studiendesigns und der Messung der Studieninhalte.\nWie ist die Studie aufgebaut?\nDesigndetails\nWas misst die Studie?\nPrim\u00e4re Ergebnismessungen\n|\n|\nErgebnis Ma\u00dfnahme\n|\n|\nZeitfenster\n|\n|\nAnzahl der Teilnehmer mit Nebenwirkungen innerhalb von 7 Tagen nach jeder Injektion\nZeitfenster: bis zu 7 Tage nach jeder Injektion\n|\n|\nbis zu 7 Tage nach jeder Injektion\nSekund\u00e4re Ergebnismessungen\n|\n|\nErgebnis Ma\u00dfnahme\n|\n|\nZeitfenster\n|\n|\nGesamtinzidenz von Nebenwirkungen innerhalb von 28 Tagen gem\u00e4\u00df CTCAE v4.0\nZeitfenster: bis zu 28 Tage nach jeder Injektion\n|\n|\nbis zu 28 Tage nach jeder Injektion\n|\n|\nAntik\u00f6rper-serologische Konversionsrate in Populationen mit Lebererkrankungen nach COVID-19-Impfung\nZeitfenster: am Tag der ersten Impfdosis (Basislinie) und 14 Tage, 28 Tage, 90 Tage und 180 Tage nach der zweiten Impfdosis\n|\n|\nam Tag der ersten Impfdosis (Basislinie) und 14 Tage, 28 Tage, 90 Tage und 180 Tage nach der zweiten Impfdosis\n|\n|\nNeutralisierende Antik\u00f6rpertiter in Blutproben nach der Impfung\nZeitfenster: am Tag der ersten Impfdosis (Basislinie) und 14 Tage, 28 Tage, 90 Tage und 180 Tage nach der zweiten Impfdosis\n|\n|\nam Tag der ersten Impfdosis (Basislinie) und 14 Tage, 28 Tage, 90 Tage und 180 Tage nach der zweiten Impfdosis\n|\n|\nAntik\u00f6rper-IgM-Titer in Blutproben nach Impfung\nZeitfenster: am Tag der ersten Impfdosis (Basislinie) und 14 Tage, 28 Tage, 90 Tage und 180 Tage nach der zweiten Impfdosis\n|\n|\nam Tag der ersten Impfdosis (Basislinie) und 14 Tage, 28 Tage, 90 Tage und 180 Tage nach der zweiten Impfdosis\n|\n|\nAntik\u00f6rper-IgG-Titer in Blutproben nach Impfung\nZeitfenster: am Tag der ersten Impfdosis (Basislinie) und 14 Tage, 28 Tage, 90 Tage und 180 Tage nach der zweiten Impfdosis\n|\n|\nam Tag der ersten Impfdosis (Basislinie) und 14 Tage, 28 Tage, 90 Tage und 180 Tage nach der zweiten Impfdosis\nMitarbeiter und Ermittler\nHier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.\nMitarbeiter\nPublikationen und hilfreiche Links\nDie Bereitstellung dieser Publikationen erfolgt freiwillig durch die f\u00fcr die Eingabe von Informationen \u00fcber die Studie verantwortliche Person. Diese k\u00f6nnen sich auf alles beziehen, was mit dem Studium zu tun hat.\nAllgemeine Ver\u00f6ffentlichungen\n-\n[Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.](https://ichgcp.net/de/clinical-trials-registry/publications/5604-efficacy-and-safety-of-the-mrna-1273-sars-cov-2-vaccine)\n-\n[Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.](https://ichgcp.net/de/clinical-trials-registry/publications/2989-clinical-characteristics-of-coronavirus-disease-2019-in-china)\n-\n[Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020 Sep 8;324(10):951-960. doi: 10.1001/jama.2020.15543.](https://ichgcp.net/de/clinical-trials-registry/publications/12334-effect-of-an-inactivated-vaccine-against-sars-cov-2-on-safety-and-immunogenicity-outcomes-interim)\n-\n[Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Li J, Yang M, Song Y, Wang X, Gao Q, Zhu F. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17.](https://ichgcp.net/de/clinical-trials-registry/publications/12337-safety-tolerability-and-immunogenicity-of-an-inactivated-sars-cov-2-vaccine-in-healthy-adults-aged)\n-\n[Cornberg M, Buti M, Eberhardt CS, Grossi PA, Shouval D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol. 2021 Apr;74(4):944-951. doi: 10.1016/j.jhep.2021.01.032. Epub 2021 Feb 6.](https://ichgcp.net/de/clinical-trials-registry/publications/41920-easl-position-paper-on-the-use-of-covid-19-vaccines-in-patients-with-chronic-liver-diseases)\n- World Health Organization. Coronavirus disease (COVID-2019) situation reports[EB/OL]. https: //www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/.\n-\n[Sarin SK, Choudhury A, Lau GK, Zheng MH, Ji D, Abd-Elsalam S, Hwang J, Qi X, Cua IH, Suh JI, Park JG, Putcharoen O, Kaewdech A, Piratvisuth T, Treeprasertsuk S, Park S, Wejnaruemarn S, Payawal DA, Baatarkhuu O, Ahn SH, Yeo CD, Alonzo UR, Chinbayar T, Loho IM, Yokosuka O, Jafri W, Tan S, Soo LI, Tanwandee T, Gani R, Anand L, Esmail ES, Khalaf M, Alam S, Lin CY, Chuang WL, Soin AS, Garg HK, Kalista K, Batsukh B, Purnomo HD, Dara VP, Rathi P, Al Mahtab M, Shukla A, Sharma MK, Omata M; APASL COVID Task Force, APASL COVID Liver Injury Spectrum Study (APCOLIS Study-NCT 04345640). Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatol Int. 2020 Sep;14(5):690-700. doi: 10.1007/s12072-020-10072-8. Epub 2020 Jul 4.](https://ichgcp.net/de/clinical-trials-registry/publications/134597-pre-existing-liver-disease-is-associated-with-poor-outcome-in-patients-with-sars-cov2-infection-the)\n-\n[Iavarone M, D'Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, Perricone G, Massironi S, Spinetti A, Buscarini E, Vigano M, Carriero C, Fagiuoli S, Aghemo A, Belli LS, Luca M, Pedaci M, Rimondi A, Rumi MG, Invernizzi P, Bonfanti P, Lampertico P. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020 Nov;73(5):1063-1071. doi: 10.1016/j.jhep.2020.06.001. Epub 2020 Jun 9.](https://ichgcp.net/de/clinical-trials-registry/publications/158377-high-rates-of-30-day-mortality-in-patients-with-cirrhosis-and-covid-19)\n-\n[Qi X, Wang J, Li X, Wang Z, Liu Y, Yang H, Li X, Shi J, Xiang H, Liu T, Kawada N, Maruyama H, Jiang Z, Wang F, Takehara T, Rockey DC, Sarin SK; COVID-Cirrhosis-CHESS Group. Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China. Hepatol Int. 2020 Jul;14(4):478-482. doi: 10.1007/s12072-020-10051-z. Epub 2020 May 22.](https://ichgcp.net/de/clinical-trials-registry/publications/134599-clinical-course-of-covid-19-in-patients-with-pre-existing-decompensated-cirrhosis-initial-report)\n-\n[Moon AM, Webb GJ, Aloman C, Armstrong MJ, Cargill T, Dhanasekaran R, Genesca J, Gill US, James TW, Jones PD, Marshall A, Mells G, Perumalswami PV, Qi X, Su F, Ufere NN, Barnes E, Barritt AS, Marjot T. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. J Hepatol. 2020 Sep;73(3):705-708. doi: 10.1016/j.jhep.2020.05.013. Epub 2020 May 21. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/32446714)\n-\n[Qi X, Liu Y, Wang J, Fallowfield JA, Wang J, Li X, Shi J, Pan H, Zou S, Zhang H, Chen Z, Li F, Luo Y, Mei M, Liu H, Wang Z, Li J, Yang H, Xiang H, Li X, Liu T, Zheng MH, Liu C, Huang Y, Xu D, Li X, Kang N, He Q, Gu Y, Zhang G, Shao C, Liu D, Zhang L, Li X, Kawada N, Jiang Z, Wang F, Xiong B, Takehara T, Rockey DC; COVID-Cirrhosis-CHESS Group. Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study. Gut. 2021 Feb;70(2):433-436. doi: 10.1136/gutjnl-2020-321666. Epub 2020 May 20. No abstract available.](https://ichgcp.net/de/clinical-trials-registry/publications/134600-clinical-course-and-risk-factors-for-mortality-of-covid-19-patients-with-pre-existing-cirrhosis-a)\n-\n[He Q, Zhang G, Gu Y, Wang J, Tang Q, Jiang Z, Shao C, Zhang H, Chen Z, Ma B, Liu D, Xie G, Xu D, Huang Y, Zhang H, Liang M, Huang H, Wang Y, Liu H, Yang J, Pan H, Zou S, Li F, Wang F, Liu C, Wang W, Xiong B, Li X, Liu L, Yang J, Qi X. Clinical Characteristics of COVID-19 Patients With Pre-existing Hepatitis B Virus Infection: A Multicenter Report. Am J Gastroenterol. 2021 Feb 1;116(2):420-421. doi: 10.14309/ajg.0000000000000924. No abstract available.](https://pubmed.ncbi.nlm.nih.gov/32925195)\nStudienaufzeichnungsdaten\nDiese Daten verfolgen den Fortschritt der \u00dcbermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) \u00fcberpr\u00fcft, um sicherzustellen, dass sie bestimmten Qualit\u00e4tskontrollstandards entsprechen, bevor sie auf der \u00f6ffentlichen Website ver\u00f6ffentlicht werden.\nHaupttermine studieren\nStudienbeginn (Tats\u00e4chlich)\n11. Mai 2021\nPrim\u00e4rer Abschluss (Tats\u00e4chlich)\n1. Januar 2022\nStudienabschluss (Tats\u00e4chlich)\n1. Mai 2022\nStudienanmeldedaten\nZuerst eingereicht\n29. April 2021\nZuerst eingereicht, das die QC-Kriterien erf\u00fcllt hat\n11. Mai 2021\nZuerst gepostet (Tats\u00e4chlich)\n12. Mai 2021\nStudienaufzeichnungsaktualisierungen\nLetztes Update gepostet (Tats\u00e4chlich)\n25. April 2023\nLetztes eingereichtes Update, das die QC-Kriterien erf\u00fcllt\n23. April 2023\nZuletzt verifiziert\n1. April 2023\nMehr Informationen\nBegriffe im Zusammenhang mit dieser Studie\nZus\u00e4tzliche relevante MeSH-Bedingungen\nAndere Studien-ID-Nummern\n- CHESS2101\nPlan f\u00fcr individuelle Teilnehmerdaten (IPD)\nPlanen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?\nUNENTSCHIEDEN\nArzneimittel- und Ger\u00e4teinformationen, Studienunterlagen\nStudiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt\nNein\nStudiert ein von der US-amerikanischen FDA reguliertes Ger\u00e4teprodukt\nNein\nDiese Informationen wurden ohne \u00c4nderungen direkt von der Website\n[clinicaltrials.gov](https://clinicaltrials.gov) abgerufen. Wenn Sie Ihre Studiendaten \u00e4ndern, entfernen oder aktualisieren m\u00f6chten, wenden Sie sich bitte an [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). Sobald eine \u00c4nderung auf [clinicaltrials.gov](https://clinicaltrials.gov) implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .\nKlinische Studien zur COVID-19\n-\nNCT06099613Rekrutierung\n-\nNCT06099795Noch keine Rekrutierung\n[Bewertung der \u00dcbereinstimmung zwischen Ausatemlufttest (eBAM-CoV) und RT-PCR zum Nachweis von SARS-CoV-2 (eBAM_CoV)](https://ichgcp.net/de/clinical-trials-registry/NCT06099795)COVID-19 | Coronavirus | SARS-CoV-2-Infektion\n-\nNCT06097403Noch keine RekrutierungCOVID-19-assoziierte Koagulopathie\n-\nNCT06097442RekrutierungPostakute Folgen einer SARS-COV-2-Infektion\n-\nNCT06096571Noch keine Rekrutierung\n-\nNCT06095258Noch keine Rekrutierung\n-\nNCT06095297Noch keine RekrutierungKognitive Beeintr\u00e4chtigung | Kognitive Dysfunktion | Lange COVID | Hirnnebel | Postakutes COVID-19-Syndrom\n-\nNCT06091280Noch keine Rekrutierung\n[Heimtrainingsprogramm f\u00fcr die Kraft der Atemmuskulatur f\u00fcr Personen mit anhaltender Dyspnoe nach COVID-19](https://ichgcp.net/de/clinical-trials-registry/NCT06091280)Dyspnoe | Post-COVID-19-Syndrom\n-\nNCT06091358Noch keine Rekrutierung\n-\nNCT06091384RekrutierungHerz-Kreislauf-Anomalien | Post-COVID-19-Syndrom | K\u00f6rperliche Bet\u00e4tigung", "language": null, "image": null, "pagetype": "website", "links": ["https://ichgcp.net/de", "#", "https://ichgcp.net/de", "https://ichgcp.net/", "https://ichgcp.net/es", "https://ichgcp.net/fr", "https://ichgcp.net/it", "https://ichgcp.net/pt", "https://ichgcp.net/ru", "https://ichgcp.net/de/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/de/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/de/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/de/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/de/ich-e-group-of-guidelines", "https://ichgcp.net/de/cro-list", "https://ichgcp.net/de/clinical-trials-registry", "https://ichgcp.net/de/eu-clinical-trials-registry", "https://ichgcp.net/de/pharma-list", "https://ichgcp.net/de/labs", "https://ichgcp.net/de/service-companies", "https://ichgcp.net/de/events", "https://ichgcp.net/de/clinical-trials-registry/publications", "https://ichgcp.net/de/clinical-trials-registry/researchers", "https://ichgcp.net/de/cra-jobs", "https://ichgcp.net/de/publications", "https://ichgcp.net/de/news", "https://ichgcp.net/clinical-trials-registry/NCT04883177", "https://telegram.me/share/url?url=https://ichgcp.net/de/clinical-trials-registry/NCT04883177&text=", "https://twitter.com/intent/tweet?url=https://ichgcp.net/de/clinical-trials-registry/NCT04883177", "https://ichgcp.net/de", "https://ichgcp.net/de/clinical-trials-registry", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Hepatopancreatobiliary%20Surgery%20Institute%20of%20Gansu%20Province", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=COVID-19", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Vaccine%20Reaction", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Liver%20Disease", "mailto:wangjt302@163.com?subject=NCT04883177, CHESS2101, Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101)", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Hepatopancreatobiliary%20Surgery%20Institute%20of%20Gansu%20Province", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=The%20First%20Affiliated%20Hospital%20of%20Anhui%20Medical%20University", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=LanZhou%20University", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Beijing%20YouAn%20Hospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Huashan%20Hospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Shandong%20Provincial%20Hospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Henan%20Provincial%20People%27s%20Hospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Third%20Affiliated%20Hospital%2C%20Sun%20Yat-Sen%20University", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Tianjin%20Third%20Central%20Hospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=The%20Central%20Hospital%20of%20Lishui%20City", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=First%20Affiliated%20Hospital%20of%20Chongqing%20Medical%20University", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=The%20First%20Affiliated%20Hospital%20of%20Xiamen%20University", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=The%20First%20People%27s%20Hospital%20of%20Yunnan", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=The%20First%20People%27s%20Hospital%20of%20Taicang", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Tianjin%20Second%20People%27s%20Hospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=People%27s%20Hospital%20of%20Ningxia%20Hui%20Autonomous%20Region", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=The%20Third%20People%27s%20Hospital%20of%20Taiyuan", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=The%20Third%20People%27s%20Hospital%20of%20Linfen%20City", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Shanxi%20Bethune%20Hospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Jingzhou%20Central%20Hospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Hospital%20of%20the%20Chengdu%20Office%20of%20the%20People%27s%20Government%20of%20Tibet%20Autonomous%20Region", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Jincheng%20People%27s%20Hospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Fuling%20Central%20Hospital%20of%20Chongqing%20City", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Baoding%20People%27s%20Hospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=The%20Third%20People%27s%20Hospital%20of%20Tibet%20Autonomous%20Region", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=The%20Sixth%20People%27s%20Hospital%20of%20Shenyang%20City", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Xingtai%20City%20People%27s%20Hospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Jinchang%20Central%20Hospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=The%20Third%20People%27s%20Hospital%20of%20Zhenjiang%20City", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Wuhan%20Jinyintan%20Hospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Yibin%20First%20People%27s%20Hospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Wuxi%20Fifth%20People%27s%20Hospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Qingyang%20People%27s%20Hospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Beilun%20Hospital%20of%20Traditional%20Chinese%20Medicine", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Qingdao%20Sixth%20People%27s%20Hospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Qishan%20Hospital%20of%20Yantai%20City", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Affiliated%20Hospital%20of%20Yunnan%20University", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=The%20Fourth%20Affiliated%20Hospital%20of%20Zhejiang%20University", "https://ichgcp.net/de/clinical-trials-registry/publications/5604-efficacy-and-safety-of-the-mrna-1273-sars-cov-2-vaccine", "https://ichgcp.net/de/clinical-trials-registry/publications/2989-clinical-characteristics-of-coronavirus-disease-2019-in-china", "https://ichgcp.net/de/clinical-trials-registry/publications/12334-effect-of-an-inactivated-vaccine-against-sars-cov-2-on-safety-and-immunogenicity-outcomes-interim", "https://ichgcp.net/de/clinical-trials-registry/publications/12337-safety-tolerability-and-immunogenicity-of-an-inactivated-sars-cov-2-vaccine-in-healthy-adults-aged", "https://ichgcp.net/de/clinical-trials-registry/publications/41920-easl-position-paper-on-the-use-of-covid-19-vaccines-in-patients-with-chronic-liver-diseases", "https://ichgcp.net/de/clinical-trials-registry/publications/134597-pre-existing-liver-disease-is-associated-with-poor-outcome-in-patients-with-sars-cov2-infection-the", "https://ichgcp.net/de/clinical-trials-registry/publications/158377-high-rates-of-30-day-mortality-in-patients-with-cirrhosis-and-covid-19", "https://ichgcp.net/de/clinical-trials-registry/publications/134599-clinical-course-of-covid-19-in-patients-with-pre-existing-decompensated-cirrhosis-initial-report", "https://pubmed.ncbi.nlm.nih.gov/32446714", "https://ichgcp.net/de/clinical-trials-registry/publications/134600-clinical-course-and-risk-factors-for-mortality-of-covid-19-patients-with-pre-existing-cirrhosis-a", "https://pubmed.ncbi.nlm.nih.gov/32925195", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Digestive%20System%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Coronavirus%20Infections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Coronaviridae%20Infections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Nidovirales%20Infections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=RNA%20Virus%20Infections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Virus%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Infections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Infections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pneumonia%2C%20Viral", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pneumonia", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Lung%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Liver%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=COVID-19", "https://clinicaltrials.gov", "mailto:register@clinicaltrials.gov", "https://clinicaltrials.gov", "https://ichgcp.net/de/clinical-trials-registry/NCT06099613", "https://ichgcp.net/de/clinical-trials-registry/NCT06099795", "https://ichgcp.net/de/clinical-trials-registry/NCT06097403", "https://ichgcp.net/de/clinical-trials-registry/NCT06097442", "https://ichgcp.net/de/clinical-trials-registry/NCT06096571", "https://ichgcp.net/de/clinical-trials-registry/NCT06095258", "https://ichgcp.net/de/clinical-trials-registry/NCT06095297", "https://ichgcp.net/de/clinical-trials-registry/NCT06091280", "https://ichgcp.net/de/clinical-trials-registry/NCT06091358", "https://ichgcp.net/de/clinical-trials-registry/NCT06091384", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=AstraZeneca", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Assistance%2BPublique%2B-%2BH%25C3%25B4pitaux%2Bde%2BParis", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Pirkanmaa%2BHospital%2BDistrict", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Sismanoglio%2B-%2BAmalia%2BFleming%2BGeneral%2BHospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Cairo%2BUniversity", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Assiut%2BUniversity", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=M.D.%2BAnderson%2BCancer%2BCenter", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=LiveRNA%2BTherapeutics%2BInc.", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=National%2BCancer%2BInstitute%2B%2528NCI%2529", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Wei%2BZhao", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Deutsche%2BGesellschaft%2Bf%25C3%25BCr%2BAllgemein-%2Bund%2BViszeralchirurgie", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Mayo%2BClinic", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Novartis%2BPharmaceuticals", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Nanjing%2BPLA%2BGeneral%2BHospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=GlaxoSmithKline", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Centre%2Bde%2Bla%2Bmain%2B-%2BCHUV", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Medical%2BSchool%2BBerlin", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Dicle%2BUniversity%2BSchool%2Bof%2BMedicine%252C%2BDiyarbakir%252C%2BTurkey", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Pfizer", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Middlesex%2BUniversity%2BLondon", "https://ichgcp.net/de/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Optic%2BNerve", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Breast%2BCancer", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Asthma", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Prostate%2BCancer", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Hypertension", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pain", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Tinea%2Bcruris", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Shouldersurgery", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Dexmedetomidine%252C%2BEsketamine%252C%2BPostoperative%2BPain%2Band%2BRecovery%2BQuality", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Intra-ocular%2BPressure", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Stroke", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Multi-kinase%2BInhibitors", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Invasive%2BDuctal%2BBreast%2BCarcinoma%2BWith%2BPredominant%2BIntraductal%2BComponent", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Minimal%2BChange%2BNephropathy", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=HIV%2BInfections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Depression", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Coronary%2BArtery%2BDisease", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Mothers", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Obesity", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Musculoskeletal%2BDisorder%2Bof%2Bthe%2BNeck", "https://ichgcp.net/de/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=bardoxolone%2Bmethyl", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Capecitabine", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=FEIBA%2Band%2BNovoSeven", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Chinese%2Bherb%2Bmedicine", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=d-amphetamine%2Bsulfate", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Dexamethasone", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Docetaxel", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Paclitaxel", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Lyndiol%25C2%25AE", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=CD30.CAR-T", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Cyclophosphamide", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=HM781-36B%2Btablets", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Gemcitabine", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Bevacizumab", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=0.3%2525%2Bhyaluronic%2Bacid%2Beye%2Bdrops", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Ketamine%2Bhigh-dose", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Prednisone", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Approved%2BICIs", "https://ichgcp.net/de/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/de/cro-list/country/albania", "https://ichgcp.net/de/cro-list/country/benin", "https://ichgcp.net/de/cro-list/country/denmark", "https://ichgcp.net/de/cro-list/country/hungary", "https://ichgcp.net/de/cro-list/country/iran", "https://ichgcp.net/de/cro-list/country/ireland", "https://ichgcp.net/de/cro-list/country/mozambique", "https://ichgcp.net/de/cro-list/country/netherlands", "https://ichgcp.net/de/cro-list/country/nigeria", "https://ichgcp.net/de/cro-list/country/poland", "https://ichgcp.net/de/cro-list/country/russia", "https://ichgcp.net/de/cro-list/country/trinidad_tobago", "https://ichgcp.net/de/cro-list/country/usa", "https://ichgcp.net/de/cro-list", "https://ichgcp.net/de/cro-list/country/nigeria/company/across_global", "https://ichgcp.net/de/cro-list/country/nigeria/company/54gene_s_clinical_programs_group_cpg", "https://ichgcp.net/de/cro-list/country/nigeria/company/celero", "https://ichgcp.net/de/cro-list/country/nigeria/company/sgs", "https://ichgcp.net/de/cro-list/country/nigeria/company/bispharm_clinical", "https://ichgcp.net/de/cro-list/country/nigeria", "https://ichgcp.net/de/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/cond_cat", "https://ichgcp.net/de/clinical-trials-registry/research/browse/ord_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/intr_cat", "https://ichgcp.net/de/clinical-trials-registry/research/browse/diet_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/diet_cat", "https://ichgcp.net/de/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/spns_cat", "https://ichgcp.net/de/clinical-trials-registry/research/browse/locn_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/locn_cat", "https://ichgcp.net/de", "https://ichgcp.net/de/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/de/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/de/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/de/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/de/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014", "https://ichgcp.net/de/cro-list", "https://ichgcp.net/de/pharma-list", "https://ichgcp.net/de/labs", "https://ichgcp.net/de/service-companies", "https://ichgcp.net/de/cra-jobs", "https://ichgcp.net/de/clinical-trials-registry", "https://ichgcp.net/de/eu-clinical-trials-registry", "https://ichgcp.net/de/publications", "https://ichgcp.net/de/news", "https://ichgcp.net/about-us-our-mission", "https://ichgcp.net/de/sitemap", "https://ichgcp.net/de/contact-us", "https://ichgcp.net/de/feed", "/privacy", "/disclaimer", "https://ichgcp.net/da/clinical-trials-registry/NCT04883177", "https://ichgcp.net/de/clinical-trials-registry/NCT04883177", "https://ichgcp.net/clinical-trials-registry/NCT04883177", "https://ichgcp.net/es/clinical-trials-registry/NCT04883177", "https://ichgcp.net/fr/clinical-trials-registry/NCT04883177", "https://ichgcp.net/it/clinical-trials-registry/NCT04883177", "https://ichgcp.net/hu/clinical-trials-registry/NCT04883177", "https://ichgcp.net/nl/clinical-trials-registry/NCT04883177", "https://ichgcp.net/no/clinical-trials-registry/NCT04883177", "https://ichgcp.net/pl/clinical-trials-registry/NCT04883177", "https://ichgcp.net/pt/clinical-trials-registry/NCT04883177", "https://ichgcp.net/fi/clinical-trials-registry/NCT04883177", "https://ichgcp.net/sv/clinical-trials-registry/NCT04883177", "https://ichgcp.net/cs/clinical-trials-registry/NCT04883177", "https://ichgcp.net/ru/clinical-trials-registry/NCT04883177", "https://ichgcp.net/ja/clinical-trials-registry/NCT04883177", "https://ichgcp.net/zh/clinical-trials-registry/NCT04883177", "https://ichgcp.net/ko/clinical-trials-registry/NCT04883177", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf"]}